PCM
KYTX icon

Prelude Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Prelude Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,438
Closed -$117K – 1601
2025
Q3 		$117K Sell
19,438
-16,809
-46% -$67.2K 0.01% 1033
2025
Q2 		$111K Sell
36,247
-31,299
-46% -$77.4K 0.01% 900
2025
Q1 		$130K Buy
67,546
+23,784
+54% +$70.3K 0.01% 1013
2024
Q4 		$164K Buy
43,762
+22,367
+105% +$107K 0.01% 1034
2024
Q3 		$105K Buy
+21,395
New +$165K 0.01% 1149

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Prelude Capital Management's KYTX Position: Q4 2025 in Review

Prelude Capital Management sold out of Kyverna Therapeutics (KYTX) in Q4 2025, closing a stake of 19,438 shares — an estimated $117K sold.

Prelude Capital Management first reported a position in KYTX in Q3 2024 and held it in 5 quarters. The position peaked at $164K in Q4 2024. 99 funds tracked by Wall St. Rank hold KYTX as of Q4 2025.

  • Prelude Capital Management reported no remaining Kyverna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 19,438 Kyverna Therapeutics shares in Q4 2025, an estimated $117K.
  • Prelude Capital Management first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 5 quarters.
  • Prelude Capital Management's Kyverna Therapeutics position peaked at $164K in Q4 2024.
  • 99 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.